{"id":"W3118507153","doi":"10.1158/1078-0432.ccr-20-3706","title":"Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":196,"is_retracted":false,"has_abstract":true,"ca_institutions":"Trillium Therapeutics (Canada); Spinal Cord Injury BC; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"National Institutes of Health","keywords":"Medicine; Refractory (planetary science); Chills; Rituximab; Lymphoma; Internal medicine; Clinical endpoint; Gastroenterology; Adverse effect; Nivolumab; Phases of clinical research; Surgery; Chemotherapy; Cancer; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007596065,0.0009785654,0.001314869,0.0002879457,0.000289792,0.0006871255,0.0004256001,0.0006789885,0.002840463],"category_scores_gemma":[0.0004169623,0.0003643015,0.0007744259,0.0002631129,0.0003595432,0.0004000748,0.0002132955,0.001682189,0.0008469248],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005949402,"about_ca_system_score_gemma":0.0009843385,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006493482,"about_ca_topic_score_gemma":0.002217527,"domain_scores_codex":[0.9998337,0.00005830498,0.00001120944,0.00003224461,0.00002407972,0.0000404556],"domain_scores_gemma":[0.999786,0.00002270808,0.00004813233,0.00001748987,0.00001790224,0.0001078413],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3926809,0.09182391,0.01917649,0.002396789,0.00248933,0.000820854,0.0006085392,0.005219415,0.166086,0.0005404467,0.01282138,0.305336],"study_design_scores_gemma":[0.45847,0.4923321,0.02392421,0.0001276661,0.0008711725,0.0008163836,0.00008736206,0.002291608,0.01058808,0.0002912608,0.01016202,0.00003804098],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9888999,0.004405322,0.0005790148,0.0003795472,0.0001017456,0.002001352,0.0007669997,0.0001357713,0.002730184],"genre_scores_gemma":[0.9892202,0.002738738,0.001120517,0.001000133,0.0001316294,0.001330118,0.001670687,0.00003140341,0.002756749],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002840463,"threshold_uncertainty_score":0.009502292,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.159802523185442,"score_gpt":0.4642106808345872,"score_spread":0.3044081576491452,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}